Right Ventricular Ejection Fraction and Beta-Blocker Effect in Heart Failure With Reduced Ejection Fraction
Phillip H. Lam(MedStar Washington Hospital Center), Ali Ahmed(Linköping University), Wen‐Chih Wu(Brown University), John G.F. Cleland(University of Glasgow), Gerasimos Filippatos(National and Kapodistrian University of Athens), Charles Faselis(Uniformed Services University of the Health Sciences), Gregg C. Fonarow(UCLA Medical Center), Prakash Deedwania(San Francisco VA Medical Center), Charity J. Morgan(University of Alabama at Birmingham), Kalliopi Keramida(National and Kapodistrian University of Athens), Brandon George(Thomas Jefferson University), Neha Gupta(MedStar Washington Hospital Center), Ami E. Iskandrian(University of Alabama at Birmingham), Gaurav Choudhary(Technical University of Denmark)
Cited by 13
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k